NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD

Overview

NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 6 active FDA Type II Drug Master Files, covering (2R,3R)-3-(2,5-DIFLUOROPHENYL)-3-HYDROXY-2-METHYL-4-(1H-1,2,4-TRIAZOL-1-YL) THIOBUTYRAMIDE; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LP-4; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPA; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPB; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPE-5; SEMAGLUTIDE DRUG SUBSTANCE INTERMEDIATE XSC.

API / Drug Master Files

NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD holds 6 active (6 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• SEMAGLUTIDE DRUG SUBSTANCE INTERMEDIATE XSCActive2026-01-14
• LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LP-4Active2025-11-06
• LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPE-5Active2025-10-17
• LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPBActive2025-09-22
• LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPAActive2025-09-22
• (2R,3R)-3-(2,5-DIFLUOROPHENYL)-3-HYDROXY-2-METHYL-4-(1H-1,2,4-TRIAZOL-1-YL) THIOBUTYRAMIDEActive2024-11-11

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.